| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $67.04 | $14.25B | N/A |
Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?
http://www.zacks.com/stock/news/296008/incyte-incy-up-52-since-earnings-report-can-it-continue?cid=CS-ZC-FT-296008
Mar 19, 2018 - Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Is Geron Corporation's Stock Set to Sail or Sink?
https://www.fool.com/investing/2018/03/18/is-geron-corporations-stock-set-to-sail-or-sink.aspx?source=iedfolrf0000001
Mar 18, 2018 - Geron's fourth-quarter earnings release raises more questions than it answers.
0
AstraZeneca's Final Data From Key Lung Cancer Study Delayed
http://www.zacks.com/stock/news/295477/astrazenecas-final-data-from-key-lung-cancer-study-delayed?cid=CS-ZC-FT-295477
Mar 13, 2018 - AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
0
The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte
http://www.zacks.com/stock/news/295028/the-zacks-analyst-blog-highlights-royal-dutch-mastercard-itau-unibanco-suncor-and-incyte?cid=CS-ZC-FT-295028
Mar 09, 2018 - The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte
0
Top Analyst Reports for Royal Dutch Shell, Mastercard & Itau Unibanco
http://www.zacks.com/research-daily/152377/top-analyst-reports-for-royal-dutch-shell-mastercard-itau-unibanco?cid=CS-ZC-FT-152377
Mar 08, 2018 - Top Analyst Reports for Royal Dutch Shell, Mastercard & Itau Unibanco
0
M&A, Innovation & New Drugs to Drive Pharma Stocks
http://www.zacks.com/commentary/152408/ma-innovation-new-drugs-to-drive-pharma-stocks?cid=CS-ZC--152408
Mar 08, 2018 - M&A, Innovation & New Drugs to Drive Pharma Stocks
0
Stocks Take the Powell Plunge
https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-ZC-FT-1607
Feb 28, 2018 - Stocks Take the Powell Plunge
0
Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo
http://www.zacks.com/stock/news/294104/biotech-stock-round-up-celgene-suffers-setback-gilead-teams-up-with-sangamo?cid=CS-ZC-FT-294104
Feb 28, 2018 - The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
0
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
http://www.zacks.com/stock/news/293094/zackscom-featured-highlights-include-incyte-altice-usa-archrock-live-nation-and-ptc?cid=CS-ZC-FT-293094
Feb 21, 2018 - Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
0
Incyte (INCY) Q4 2017 Earnings Conference Call Transcript
https://www.fool.com/earnings/call-transcripts/2018/02/20/incyte-incy-q4-2017-earnings-conference-call-trans.aspx?source=iedfolrf0000001
Feb 20, 2018 - INCY earnings call for the period ending December 31, 2017.
0